Patents by Inventor Arnon Rosenthal

Arnon Rosenthal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-SIGLEC-9 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20240067723
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: April 10, 2023
    Publication date: February 29, 2024
    Applicant: Alector LLC
    Inventors: Arnon Rosenthal, Kate Monroe, Seung-Joo Lee
  • Anti-MerTK antibodies and methods of use thereof
    Patent number: 11897968
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MerTK polypeptide, e.g., a mammalian MerTK or human MerTK, and use of such compositions in treating an individual in need thereof.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: February 13, 2024
    Assignee: ALECTOR LLC
    Inventors: Seung-Joo Lee, Spencer Liang, Angie Yee, Marina Roell, Arnon Rosenthal
  • HUMANIZED ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF
    Publication number: 20240025974
    Abstract: The present disclosure is directed to humanized anti-C1q antibodies and methods of using them.
    Type: Application
    Filed: January 24, 2023
    Publication date: January 25, 2024
    Inventors: Arnon Rosenthal, Michael Leviten
  • Anti-SIRP-alpha antibodies and methods of use thereof
    Patent number: 11779642
    Abstract: The invention provides anti-SIRPA antibodies, methods of generating such antibodies, and therapeutic uses and methods employing the antibodies.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: October 10, 2023
    Assignee: Alector LLC
    Inventors: Andrew Pincetic, Arnon Rosenthal, Seung-Joo Lee
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230312712
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: February 24, 2023
    Publication date: October 5, 2023
    Applicant: Alectro LLC
    Inventors: Tina SCHWABE, Eric BROWN, Philip KONG, Ilaria TASSI, Seung-Joo LEE, Arnon ROSENTHAL, Robert PEJCHAL, Nels P. NIELSON
  • ANTI-TMEM106B ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230303681
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: August 18, 2022
    Publication date: September 28, 2023
    Inventors: Arnon ROSENTHAL, Eric BROWN, Tina SCHWABE, Angie YEE, Herve RHINN
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230295297
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: February 17, 2023
    Publication date: September 21, 2023
    Applicant: Alector LLC
    Inventors: Tina SCHWABE, Fracesca AVOGADRI-CONNORS, Helen LAM, Ilaria TASSI, Seung-Joo LEE, Arnon ROSENTHAL
  • METHODS OF USE OF ANTI-TREM2 ANTIBODIES
    Publication number: 20230183341
    Abstract: The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a TREM2 protein, e.g., human TREM2, for use in treating and/or delaying progression of a disease or injury in an individual in need thereof.
    Type: Application
    Filed: April 2, 2021
    Publication date: June 15, 2023
    Applicant: Alector LLC
    Inventors: Robert PAUL, Michael F. WARD, Hua LONG, Omer Rizwan SIDDIQUI, Arnon ROSENTHAL, Felix Leejia YEH, Sam JACKSON
  • Anti-Siglec-9 antibodies and methods of use thereof
    Patent number: 11667710
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: June 6, 2023
    Assignee: Alector LLC
    Inventors: Arnon Rosenthal, Kate Monroe, Seung-Joo Lee
  • Anti-MS4A4A antibodies and methods of use thereof
    Patent number: 11667699
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: June 6, 2023
    Assignee: Alector LLC
    Inventors: Jeonghoon Sun, Wei-Hsien Ho, Muhammad A. Alhawagri, Philip Ling Kong, Herve Rhinn, Hua Long, Karpagam Srinivasan, Ananya Mitra, Daniel P. Bermingham, Klaus-Dieter Heger, Santiago Viveros Salazar, Francesca Cignarella, Ilaria Tassi, Tina Schwabe, Angie Grace Yee, Arnon Rosenthal
  • METHODS OF USE OF ANTI-TREM2 ANTIBODIES
    Publication number: 20230159637
    Abstract: The present disclosure is generally directed to the use of anti-TREM2 antibodies in preventing, reducing risk, or treating disease in an individual in need thereof.
    Type: Application
    Filed: February 23, 2021
    Publication date: May 25, 2023
    Applicants: Alector LLC, Washington University
    Inventors: Francesca CIGNARELLA, Fabia FILIPELLO, Bryan BOLLMAN, Arnon ROSENTHAL, Tina SCHWABE, Ilaria TASSI, Laura PICCIO
  • Anti-complement factor C1Q antibodies and uses thereof
    Patent number: 11649279
    Abstract: The present invention provides anti-C1q antibodies and methods of using the same.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: May 16, 2023
    Assignee: Annexon, Inc.
    Inventors: Arnon Rosenthal, Michael Leviten
  • ANTI-MS4A4A ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230142579
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: August 19, 2022
    Publication date: May 11, 2023
    Inventors: Philip KONG, Herve RHINN, Tina SCHWABE, Angie YEE, Ilaria TASSI, Muhammad Abbas ALHAWAGRI, Arnon ROSENTHAL
  • ANTI-MS4A4A ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230126400
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc.. that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: August 19, 2022
    Publication date: April 27, 2023
    Inventors: Philip KONG, Herve RHINN, Tina SCHWABE, Angie YEE, Ilaria TASSI, Muhammad Abbas ALHAWAGRI, Arnon ROSENTHAL
  • Anti-TREM2 antibodies and methods of use thereof
    Patent number: 11634489
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: April 25, 2023
    Assignee: Alector LLC
    Inventors: Tina Schwabe, Eric Brown, Philip Kong, Ilaria Tassi, Seung-Joo Lee, Arnon Rosenthal, Robert Pejchal, Nels P. Nielson
  • Anti-TREM1 Antibodies and Methods of Use Thereof
    Publication number: 20230121869
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM1 protein, e.g., a mammalian TREM1 or human TREM1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: September 13, 2022
    Publication date: April 20, 2023
    Applicant: Alector LLC
    Inventors: Andrew Pincetic, Arnon Rosenthal, Helen Lam, Francesca Avogadri-Connors, Seung-Joo Lee
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230107639
    Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.
    Type: Application
    Filed: April 21, 2022
    Publication date: April 6, 2023
    Applicant: Alector LLC
    Inventors: Kate MONROE, Tina SCHWABE, Francesca AVOGADRI-CONNORS, Ilaria TASSI, Helen LAM, Arnon ROSENTHAL
  • ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230047941
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: June 9, 2022
    Publication date: February 16, 2023
    Applicant: Alector LLC
    Inventors: Tina SCHWABE, Michael KURNELLAS, Arnon ROSENTHAL, Robert PEJCHAL, Anthony B. COOPER
  • METHODS OF USE OF ANTI-CD33 ANTIBODIES
    Publication number: 20230035072
    Abstract: The present disclosure is generally directed to antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics. The present disclosure is further directed to the methods of treating and/or delaying the progression of a disease or injury in an individual by administering such antibodies.
    Type: Application
    Filed: December 11, 2020
    Publication date: February 2, 2023
    Applicant: Alector LLC
    Inventors: Robert PAUL, Michael F. WARD, Hua LONG, Shiao-Ping LU, Omer Rizwan SIDDIQUI, Arnon ROSENTHAL
  • METHODS OF USE OF ANTI-TREM2 ANTIBODIES
    Publication number: 20230024528
    Abstract: The present disclosure is generally directed to the use of anti-TREM2 antibodies in preventing, reducing risk, or treating disease in an individual in need thereof.
    Type: Application
    Filed: December 4, 2020
    Publication date: January 26, 2023
    Applicant: Alector LLC
    Inventors: Tina SCHWABE, Ilaria TASSI, Arnon ROSENTHAL, Hua LONG, Santiago Viveros SALAZAR